mRNA-based immunotherapy improves the efficacy of adoptively transferred TCR transgenic T cells in a murine solid tumour model
Results demonstrate that mRNA immunotherapy can substantially enhance the efficacy of TCRtg T cell therapy in a solid tumour model, and holds promise for overcoming key limitations of ACT by boosting T cell expansion, persistence, infiltration, and functional capacity within the tumour microenvironment.